Literature DB >> 30840885

Human Pluripotent Stem Cell-Derived Tumor Model Uncovers the Embryonic Stem Cell Signature as a Key Driver in Atypical Teratoid/Rhabdoid Tumor.

Yukinori Terada1, Norihide Jo2, Yoshiki Arakawa3, Megumi Sakakura4, Yosuke Yamada2, Tomoyo Ukai4, Mio Kabata2, Kanae Mitsunaga2, Yohei Mineharu3, Sho Ohta5, Masato Nakagawa2, Susumu Miyamoto3, Takuya Yamamoto6, Yasuhiro Yamada7.   

Abstract

Atypical teratoid/rhabdoid tumor (AT/RT), which harbors SMARCB1 mutation and exhibits a characteristic histology of rhabdoid cells, has a poor prognosis because of the lack of effective treatments. Here, we establish human SMARCB1-deficient pluripotent stem cells (hPSCs). SMARCB1-deficient hPSC-derived neural progenitor-like cells (NPLCs) efficiently give rise to brain tumors when transplanted into the mouse brain. Notably, activation of an embryonic stem cell (ESC)-like signature confers a rhabdoid histology in SMARCB1-deficient NPLC-derived tumors and causes a poor prognosis. Consistently, we find the activation of the ESC-like gene expression signature and an ESC-like DNA methylation landscape in clinical specimens of AT/RT. Finally, we identify candidate genes that maintain the activation of the ESC-like signature and the growth of AT/RT cells. Collectively, SMARCB1-deficient hPSCs offer the human models for AT/RT, which uncover the role of the activated ESC-like signature in the poor prognosis and unique histology of AT/RT.
Copyright © 2019 The Author(s). Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ESC-like signature; SMARCB1; atypical teratoid/rhabdoid tumor; dedifferentiation; embryonic stem cell; induced pluripotent stem cell; pediatric tumor; pluripotency

Mesh:

Year:  2019        PMID: 30840885     DOI: 10.1016/j.celrep.2019.02.009

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  12 in total

Review 1.  Cancer Stem Cells and Neuroblastoma: Characteristics and Therapeutic Targeting Options.

Authors:  Veronica Veschi; Francesco Verona; Carol J Thiele
Journal:  Front Endocrinol (Lausanne)       Date:  2019-11-19       Impact factor: 5.555

2.  Whole-genome sequencing analysis of an atypical teratoid/rhabdoid tumor in a patient with Phelan-McDermid syndrome: a case report and systematic review.

Authors:  Haruki Yamashita; Yoshiki Arakawa; Yukinori Terada; Yasuhide Takeuchi; Yohei Mineharu; Sosuke Sumiyoshi; Shinya Tokunaga; Kohei Nakajima; Naoko Kawabata; Kuniaki Tanaka; Masahiro Tanji; Katsutsugu Umeda; Sachiko Minamiguchi; Seishi Ogawa; Hironori Haga; Junko Takita; Susumu Miyamoto
Journal:  Brain Tumor Pathol       Date:  2022-06-24       Impact factor: 3.154

Review 3.  The current landscape of immunotherapy for pediatric brain tumors.

Authors:  Eugene I Hwang; Elias J Sayour; Catherine T Flores; Gerald Grant; Robert Wechsler-Reya; Lan B Hoang-Minh; Mark W Kieran; Joanne Salcido; Robert M Prins; John W Figg; Michael Platten; Kate M Candelario; Paul G Hale; Jason E Blatt; Lance S Governale; Hideho Okada; Duane A Mitchell; Ian F Pollack
Journal:  Nat Cancer       Date:  2022-01-20

Review 4.  The Organoid Era Permits the Development of New Applications to Study Glioblastoma.

Authors:  Francesco Andreatta; Giulia Beccaceci; Nicolò Fortuna; Martina Celotti; Dario De Felice; Marco Lorenzoni; Veronica Foletto; Sacha Genovesi; Josep Rubert; Alessandro Alaimo
Journal:  Cancers (Basel)       Date:  2020-11-09       Impact factor: 6.639

Review 5.  In vitro Modeling of Embryonal Tumors.

Authors:  Lars Custers; Irene Paassen; Jarno Drost
Journal:  Front Cell Dev Biol       Date:  2021-02-26

Review 6.  Modeling cancer progression using human pluripotent stem cell-derived cells and organoids.

Authors:  Meili Zhang; J Jeya Vandana; Lauretta Lacko; Shuibing Chen
Journal:  Stem Cell Res       Date:  2020-10-27       Impact factor: 2.020

7.  Dual mTORC1/2 inhibition compromises cell defenses against exogenous stress potentiating Obatoclax-induced cytotoxicity in atypical teratoid/rhabdoid tumors.

Authors:  Ashlyn Parkhurst; Sabrina Z Wang; Tyler R Findlay; Kristen J Malebranche; Arman Odabas; Jesse Alt; Micah J Maxwell; Harpreet Kaur; Cody J Peer; William D Figg; Katherine E Warren; Barbara S Slusher; Charles G Eberhart; Eric H Raabe; Jeffrey A Rubens
Journal:  Cell Death Dis       Date:  2022-04-28       Impact factor: 8.469

Review 8.  Genome Engineering Evolves Brain Tumor Modeling.

Authors:  Tomoyuki Koga; Clark C Chen; Frank B Furnari
Journal:  Neurol Med Chir (Tokyo)       Date:  2020-06-15       Impact factor: 1.742

9.  De Novo DNA Methylation at Imprinted Loci during Reprogramming into Naive and Primed Pluripotency.

Authors:  Masaki Yagi; Mio Kabata; Tomoyo Ukai; Sho Ohta; Akito Tanaka; Yui Shimada; Michihiko Sugimoto; Kimi Araki; Keisuke Okita; Knut Woltjen; Konrad Hochedlinger; Takuya Yamamoto; Yasuhiro Yamada
Journal:  Stem Cell Reports       Date:  2019-05-02       Impact factor: 7.765

10.  Human Pluripotent Stem Cell Fate Regulation by SMARCB1.

Authors:  Ilana Carmel-Gross; Etgar Levy; Leah Armon; Orly Yaron; Hiba Waldman Ben-Asher; Achia Urbach
Journal:  Stem Cell Reports       Date:  2020-10-29       Impact factor: 7.765

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.